PROSCA & BLADDR 2022
BLADDR
PROSCA & BLADDR 2022
Neoadjuvant Systemic Therapy for MIBC
FEATURING
Thomas Powles
- 556 views
- December 28, 2022
- 2
PROSCA & BLADDR 2022
Update on Perioperative Systemic Therapies for UTUC
FEATURING
Kilian Gust
- 81 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
New Roadmaps for Bladder Preservation in High-Risk NMIBC in 2022
FEATURING
Jacques Irani
- 56 views
- December 28, 2022
PROSCA & BLADDR 2022
The Role of Systemic Therapy for Bladder Preservation Strategies in MIBC
FEATURING
Aristotelis Bamias
- 46 views
- December 28, 2022
PROSCA & BLADDR 2022
Intravesical IO in High Risk NMIBC: A HGUCG Study
FEATURING
Charalampos Fragkoulis
- 16 views
- December 28, 2022
PROSCA & BLADDR 2022
Transurethral Resection of Bladder Tumor
FEATURING
Marco Moschini
- 13 views
- December 28, 2022
PROSCA & BLADDR 2022
Genomic and Tumor Characterisation of UTUC
FEATURING
Eva Comperat
- 45 views
- December 28, 2022
PROSCA & BLADDR 2022
Clinical Utility of ctDNA Analysis in Bladder Cancer
FEATURING
Bernadett Szabados
- 78 views
- December 28, 2022
PROSCA & BLADDR 2022
The Role of Palliative and Best Supportive Care in Bladder Cancer
FEATURING
Daan De Maeseneer
- 26 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
Lessons From Failed Clinical Trials for Bladder Cancer
FEATURING
Robert Jones
- 8 views
- December 28, 2022
PROSCA & BLADDR 2022
Multiple Cases Discussion: Oligometastatic Bladder Cancer
- 111 views
- December 28, 2022
PROSCA & BLADDR 2022
Transurethral Resection of Bladder Tumor: Challenges and Opportunities
FEATURING
Marco Moschini
- 7 views
- December 28, 2022
PROSCA & BLADDR 2022
Considerations for Radical Cystectomy
FEATURING
Badrinath Konety
- 15 views
- December 28, 2022
PROSCA & BLADDR 2022
RT of the Bladder: Clinical Practice and Recent Advancements
FEATURING
Ananya Choudhury
- 70 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
The Emerging Role of Maintenance Therapy in Bladder Cancer
FEATURING
Robert Jones
- 97 views
- December 28, 2022
PROSCA & BLADDR 2022
The Growing Landscape of Antibody-Drug Conjugates in Advanced UC
FEATURING
Petros Grivas
- 116 views
- December 28, 2022
PROSCA & BLADDR 2022
Clarifying the Position of Immunotherapies for mUC
FEATURING
Bernadett Szabados
- 49 views
- December 28, 2022
PROSCA & BLADDR 2022
DEBATE: Are We Evolving Towards a Platinum-Free Future in Bladder Cancer? PRO
FEATURING
Maria De Santis
- 50 views
- December 28, 2022
PROSCA & BLADDR 2022
DEBATE: Are We Evolving Towards a Platinum-Free Future in Bladder Cancer? CON
FEATURING
Aristotelis Bamias
- 84 views
- December 28, 2022
PROSCA & BLADDR 2022
Final Results of the HIVEC-HR Randomised Trial Comparing Hyperthermic MMC vs. BCG in High-Risk NMIBC
FEATURING
Félix Guerrero-Ramos
- 37 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
Concurrent CRT for MIBC Using 5-Fluorouracil vs. Capecitabine: A Nationwide Cohort Study
FEATURING
Lisa van Hoogstraten
- 57 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
Assessment of Molecular Biomarkers for Bladder Cancer Diagnosis, Prognosis, and Therapy
FEATURING
Hajar El Ahanidi
- 40 views
- December 28, 2022
PROSCA & BLADDR 2022
Bladder Cancer Case Discussion: Staging and Follow-Up of Pts With Non-Metastatic Disease
FEATURING
Tobias Klatte,
Dionysios Mitropoulos,
Jacques Irani,
Richard Meijer,
Marco Moschini,
Nick James
- 87 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
Bladder Cancer: Is It Time to Revise the Pathway?
FEATURING
Nick James
- 292 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
Radical Cystectomy With Ileal Conduit: Lessons to Be Learned
FEATURING
Richard Meijer
- 56 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
Uro-Stoma Care: Where Are We Now
FEATURING
Bente Thoft Jensen
- 16 views
- December 28, 2022
PROSCA & BLADDR 2022
Urinary Biomarkers in Bladder Cancer Surveillance: Where Do We Stand?
FEATURING
Tobias Klatte
- 47 views
- December 28, 2022